quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:23:02·646d
SECFiling
Eloxx Pharmaceuticals Inc. logo

Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

ELOX· Eloxx Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ELOX
    Eloxx Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Dec 17UpdateOppenheimer$4.00
  • Nov 18UpdateHC Wainwright & Co.$1.00
  • Nov 11UpdateHC Wainwright & Co.$2.00
  • Jun 30UpdateMizuho$3.10

Related

  • SEC520d
    SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.
  • PR527d
    Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
  • INSIDER553d
    Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)
  • INSIDER553d
    Director Androski Lindsay was granted 12,000 shares (SEC Form 4)
  • INSIDER553d
    Director Rubin Steven D was granted 12,000 shares (SEC Form 4)
  • SEC553d
    Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • INSIDER553d
    PRESIDENT AND CEO Aggarwal Sumit was granted 165,000 shares, increasing direct ownership by 3,347% to 169,930 units (SEC Form 4)
  • 13D/G611d
    Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022